Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on June 17, 2019, 11:04:27 am

Title: First Large Study Shows Liver Fibrosis Improvement in People With NASH
Post by: Hep Editors on June 17, 2019, 11:04:27 am

People taking Ocaliva (obeticholic acid, or OCA) saw a significant improvement in liver fibrosis related to non-alcoholic steatohepatitis (NASH), according to a study presented at the 2019 International Liver Congress last week in Vienna.

“There is an urgent need for effective treatment regimens for NASH, a common liver disease which can lead to cirrhosis, liver failure and need for transplant,”  Zobair Younossi, MD, PhD, of Inova Fairfax Medical Campus in Falls Church, Virginia, said in a conference press release. “These first results from the REGENERATE study give us hope that a new targeted approach to NASH treatment may soon become available and potentially reverse some of the liver damage associated with this important liver disease.”

For more...
https://www.hepmag.com/article/fibrosis-ocaliva-nash